- Home
- BIVI vs TENX Comparison
BIVI vs TENX Comparison
Compare BIVI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- TENX
- Stock Information
- Founded
- BIVI 2013
- TENX 1967
- Country
- BIVI United States
- TENX United States
- Employees
- BIVI N/A
- TENX N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- TENX Health Care
- Exchange
- BIVI Nasdaq
- TENX Nasdaq
- Market Cap
- BIVI 18.8M
- TENX 21.7M
- IPO Year
- BIVI N/A
- TENX N/A
- Fundamental
- Price
- BIVI $0.86
- TENX $6.28
- Analyst Decision
- BIVI Strong Buy
- TENX Strong Buy
- Analyst Count
- BIVI 1
- TENX 3
- Target Price
- BIVI $30.00
- TENX $16.00
- AVG Volume (30 Days)
- BIVI 230.4K
- TENX 20.7K
- Earning Date
- BIVI 05-13-2025
- TENX 05-13-2025
- Dividend Yield
- BIVI N/A
- TENX N/A
- EPS Growth
- BIVI N/A
- TENX N/A
- EPS
- BIVI N/A
- TENX N/A
- Revenue
- BIVI N/A
- TENX N/A
- Revenue This Year
- BIVI N/A
- TENX N/A
- Revenue Next Year
- BIVI N/A
- TENX N/A
- P/E Ratio
- BIVI N/A
- TENX N/A
- Revenue Growth
- BIVI N/A
- TENX N/A
- 52 Week Low
- BIVI $0.80
- TENX $2.77
- 52 Week High
- BIVI $7.50
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- BIVI 36.17
- TENX 46.43
- Support Level
- BIVI $0.80
- TENX $6.00
- Resistance Level
- BIVI $1.00
- TENX $6.48
- Average True Range (ATR)
- BIVI 0.10
- TENX 0.38
- MACD
- BIVI 0.01
- TENX 0.00
- Stochastic Oscillator
- BIVI 29.24
- TENX 22.38
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.